Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and…

Posted: June 4, 2022 at 2:45 am

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro) inhibitor, STI-1558.

See the original post here:
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and...

Related Posts